Sites Menu > Medication Information - Antiplatelets


Medication Information - Antiplatelets


Aspirin reduces risk of cardiovascular events, increases risk of bleeding


New Data on Aspirin vs. Warfarin in TIA Patients, but Questions Persist

Henry I. Bussey, Pharm.D., FCCP, FAHA March, 2005

Alternatives to coumadin® (= warfarin)

Last Updated: 4/26/2007

Aggrenox® (aspirin/extended-release dipyridamole)

Prescribing Information - 2007

Biological efficacy of low versus medium dose aspirin after coronary surgery: results from a randomized trial

BMC Medicine 2006, 4:12. doi:10.1186/1741-7015-4-12. Conclusions: Contrary to recent findings, low dose aspirin is effective and medium dose aspirin did not prove superior for inhibiting platelet aggregation after coronary surgery.

Aspirin resistance found to raise risk for heart attack, strokes

Testing patients for resistance is becoming more common, but it's not clear how useful this information is or what to do with it.

Plavix

Drug commonly given to heart and stroke patients to reduce plaque buildup (clots).

Antiplatelet Agents in the Prevention of Atherothrombotic Events

CVD is a complex and burdensome group of illnesses. Atherothrombosis is a feature common to the most devastating of the CV events. Low-dose aspirin and clopidogrel have been shown to substantially reduce the incidence of vascular events in a variety of patient populations, while simultaneously increasing the risk of major hemorrhage. Thus, it is imperative that these agents be utilized when appropriate, yet monitored closely. Pharmacists can play a crucial role in the management of CVD generally and in the utilization of antiplatelet agents in particular.

Clopidogrel Bisulfate Oral - Plavix

WedMD Health

Aspirin Resistance: Is it Real? Is it Clinically Significant?

The American Journal of Medicine. Volume 120, Issue 1 , January 2007, Pages 1-4.

Daily aspirin therapy

Is an aspirin a day the right thing for you? It's not as easy a decision as it sounds. Know the benefits and risks first.

Antiplatelet Therapy

November 2004 Antiplatelet agents are drugs which interfere with the ability of platelets to aggregate and form a platelet plug. As antithrombotic agents, they are most useful in clinical states due to arterial vascular disease.

Aspirin, Plavix®, Coumadin® - when to use what

Veins are made up very differently compared to arteries. Veins are thin blood vessels with slow flowing blood. Blood clots that form in veins (deep vein thrombosis, pulmonary embolism) are mainly made up of clotting proteins; platelets do not play a big role in venous clots. Coumadin (= warfarin) is an effective "blood thinner" by preventing the production of clotting factors in the liver, increasing the INR. It is therefore the drug of choice in venous thrombosis. Anti-platelet drugs do not play much of a role in preventing venous clots.





 

 

The APS Foundation of America, Inc. website and forums are both volunteer run and funded by donations to the APSFA.

Website hosted by Dreamhost. Website created and maintained by Heidi P.

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

APS Foundation of America, Inc. will be building a database with your email, name and address information for future mailings. Your information will be kept confidential and not sold to any third parties. You may opt out at anytime by emailing us.

APSFA ©2005-2016 | APSFA Privacy Policy | APSFA Advertising Policy | 501(c)3 Public Charity EIN #203085295